Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2018-12-03 Board/Management Inform…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 3, 2018, reporting the appointment of a new Chief Financial Officer, James Levine. The content focuses on management changes, including biographical details and employment terms. There are no financial statements or earnings data, nor is this a report or announcement of a report publication. The key item is the departure and appointment of directors or officers, which fits the Board/Management Information category (MANG).
2018-12-03 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to a controlled equity offering of common stock. It includes detailed information about the offering, risk factors, company overview, and terms of the sale. This type of document is a registration statement prospectus used for capital raising and financing activities. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full prospectus text, not just an announcement or link to a report, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2018-11-16 English
Regulatory Filings 2018
Regulatory Filings
2018-11-16 English
AMENDMENT NO.2 TO SCHEDULE 13D
Major Shareholding Notification
2018-11-13 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock option plans or employee stock purchase plans. It includes details about the securities to be registered, the plans under which they are offered, and legal exhibits. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is over 10,000 characters and contains detailed registration information, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA).
2018-11-08 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report 9M 2018
2018-11-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.